Loading clinical trials...
Loading clinical trials...
Preliminary Evaluation of Dalbavancin's Efficacy in People Who Use Drugs With Severe Gram-positive Infections
Conditions
Interventions
Dalbavancin
Locations
1
United States
University of Colorado Hospital
Aurora, Colorado, United States
Start Date
April 30, 2021
Primary Completion Date
October 5, 2023
Completion Date
October 5, 2023
Last Updated
October 19, 2023
NCT06413979
NCT05492825
NCT04197921
NCT07210268
NCT06677515
NCT06320015
Lead Sponsor
University of Colorado, Denver
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions